AGENUS INC
AGENAgenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
Drugs in Pipeline
10
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
AGEN Earnings Report
EPS Est: $0.05 | FQ end 2026-06
How AGEN's past catalysts played out
HSPPC-96 or Oncophage
Malignant Melanoma
autologous human tumor-derived HSPPC-96
Renal Cell Carcinoma
AGEN2034
Advanced Cancer
AGEN1884
Cervical Cancer
AGEN1884 + AGEN2034
Cervical Cancer
Zalifrelimab
Advanced Solid Cancers
HerpV and QS-21
Herpes Simplex Type 2
Botensilimab
Metastatic Pancreatic Ductal Adenocarcinoma
HSPPC-96
Non-Small-Cell Lung Carcinoma
Balstilimab
Advanced Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HSPPC-96 or Oncophage | Phase 3 | Malignant Melanoma | - | - |
autologous human tumor-derived HSPPC-96 | Phase 3 | Renal Cell Carcinoma | - | - |
AGEN2034 | Phase 2 | Advanced Cancer | - | - |
AGEN1884 | Phase 2 | Cervical Cancer | - | - |
AGEN1884 + AGEN2034 | Phase 2 | Cervical Cancer | - | - |
Zalifrelimab | Phase 2 | Advanced Solid Cancers | - | - |
HerpV and QS-21 | Phase 2 | Herpes Simplex Type 2 | - | - |
Botensilimab | Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
HSPPC-96 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Balstilimab | Phase 2 | Advanced Melanoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AGENUS INC's drug pipeline?→
CatalystAlert tracks 10 drug candidates in AGENUS INC's (AGEN) pipeline across Phase 3, Phase 2. Its lead program is HSPPC-96 or Oncophage (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AGENUS INC's next FDA catalyst?→
AGENUS INC's (AGEN) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AGEN biotech catalysts?→
Add AGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AGENUS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.